77 results
POS AM
SPRC
SciSparc Ltd
17 Jun 24
Prospectus update (post-effective amendment)
4:05pm
, agonist for the treatment of pain. This innovative CB2 receptor agonist was synthesized by Raphael Mechoulam, Ph.D., Professor of Medicinal Chemistry … , including: (i) innovative vehicle models and the manner in which these are branded among customers; (ii) trade conditions, especially the exchange
6-K
EX-99.1
SPRC
SciSparc Ltd
3 Jun 24
SciSparc Secures Strategic Advantage with Grant of European Patent
7:13am
in Canada and Europe, since the beginning of the year. This aggressive expansion emphasizes SciSparc’s commitment to securing its innovative technologies
POS AM
SPRC
SciSparc Ltd
2 May 24
Prospectus update (post-effective amendment)
5:17pm
receptor type 2, or CB2 receptor, agonist for the treatment of pain. This innovative CB2 receptor agonist was synthesized by Raphael Mechoulam, Ph.D
20-F/A
2023 FY
SPRC
SciSparc Ltd
2 May 24
Annual report (foreign) (amended)
9:18am
several innovative immunotherapy products and SciSparc’s own patents in the immunotherapy field. In August 2015, the Company decided to adopt … , developing innovative medications based on the active generic substance flumazenil, including a sublingual spray to reduce the side effects of hypnotic
6-K
EX-99.1
ho5ief
15 Mar 24
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
8:00am
6-K
EX-99.1
6o3c rmfhq48dx37
29 Feb 24
Report of Foreign Private Issuer
9:07am
F-1
9yq5g py0o3k2w28xu0
27 Feb 24
Registration statement (foreign)
4:15pm
6-K
EX-99.1
6yfyd1ki
28 Nov 23
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
4:00pm
6-K
EX-99.1
0q9alc96bx
18 Oct 23
Report of Foreign Private Issuer
6:54am
6-K
EX-99.2
sx4fce qe891g8h
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
6-K
EX-99.1
s45yyk jxtj
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
6-K
EX-99.2
0fvvten
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
EX-99.1
w9q8gm2 3qw
19 Sep 23
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
6:16pm
6-K
EX-99.1
b6yofn2nc
2 Aug 23
Report of Foreign Private Issuer
12:00am
6-K
EX-99.1
b1pirn9
30 Jun 23
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
4:10pm
6-K
EX-99.1
fljc55oe8u
2 Jun 23
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
9:04am
6-K
EX-99.1
9ka 51w3qgt1d7z6kfnt
2 May 23
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer’s Disease and Agitation
7:28am
6-K
EX-99.2
x13v882
29 Dec 22
Interim Consolidated Financial Statements
4:03pm